BioVectra Enters Into Agreement With Sandoz
BioVectra has signed agreements with Sandoz, whereunder Sandoz will commercialise and market the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of Taxotere developed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.